Contingent Consideration - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands				2 Months Ended	12 Months Ended
	Apr. 26, 2022	Nov. 03, 2020	Jul. 12, 2019	Jun. 10, 2022	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Business Acquisition [Line Items]
Estimated future contingent consideration						$ 6,090	$ 5,390
Change in value of contingent consideration for acquired in-process research and development					$ 86	700
Contingent consideration						$ 6,090
Common Stock Issued Related To Contingent Consideration Liability					6,176
Clinical Trial Notification [Member]
Business Acquisition [Line Items]
Shares issued for contingent milestone payment		1,694,906
Common Stock Issued Related To Contingent Consideration Liability		$ 13,600
Spitfire Pharma, Inc. [Member]
Business Acquisition [Line Items]
Agreement date			Jul. 08, 2019
Unregistered shares of common stock			1,887,250
Up-front consideration			$ 5,000
Spitfire Pharma, Inc. [Member] | Clinical Trial Notification [Member]
Business Acquisition [Line Items]
Consideration amount		$ 9.57
Spitfire Pharma, Inc. [Member] | Investigational New Drug Application Milestone [Member]
Business Acquisition [Line Items]
Estimated future contingent consideration			$ 5,000
Estimated future contingent consideration term			60 days
Number of consecutive trading days			20 days
Consideration amount			$ 2.95
Spitfire Pharma, Inc. [Member] | Investigational New Drug Application and Regulatory Milestones [Member]
Business Acquisition [Line Items]
Estimated future contingent consideration			$ 3,000
Estimated future contingent consideration term			60 days
Number of consecutive trading days			20 days
Consideration amount			$ 3.54
Spitfire Pharma, Inc. [Member] | Sales Milestones [Member]
Business Acquisition [Line Items]
Estimated future contingent consideration			$ 80,000
License agreement term			10 years
Spitfire Pharma, Inc. [Member] | Phase Two Milestone [Member]
Business Acquisition [Line Items]
Estimated future contingent consideration					$ 0
Consideration amount	$ 8.55
Shares issued for contingent milestone payment	847,444
Change in value of contingent consideration for acquired in-process research and development				$ 1,900
Common Stock Issued Related To Contingent Consideration Liability	$ 7,200
Spitfire Pharma, Inc. [Member] | Common Stock [Member] | Maximum [Member]
Business Acquisition [Line Items]
Estimated future contingent consideration			$ 88,000